IBRX261113C00009000
IBRX Nov 13 2026 9.00 Call
optionOPRA
EODOct 16, 2026
1.19USD-38.021%(-0.73)5Vol12OI
Loading…
Underlying
Underlying Price
$8.48
Type
Call
Strike
9
Expiration
Nov 13, 2026
DTE
24d
Moneyness
OTM
Intrinsic
$0.00
IBRX 9 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $0.50 | -60.00% | 168 | 243 |
| Oct 30, 2026 | 10d | $0.74 | -50.67% | 437 | 1,164 |
| Nov 6, 2026 | 17d | $1.10 | -26.17% | 18 | 64 |
| Nov 13, 2026 | 24d | $1.19 | -38.02% | 5 | 12 |
| Nov 20, 2026 | 31d | $1.10 | -38.89% | 40 | 5,958 |
| Nov 27, 2026 | 38d | $1.86 | +0.00% | 10 | 10 |
| Dec 18, 2026 | 59d | $2.00 | +0.00% | 400 | 400 |
| Jan 15, 2027 | 87d | $1.87 | -25.20% | 64 | 6,730 |
| Mar 19, 2027 | 150d | $2.30 | -24.09% | 73 | 428 |
| Apr 16, 2027 | 178d | $3.40 | -12.82% | 1 | 42 |
| May 21, 2027 | 213d | $4.00 | +65.29% | 1 | 14 |
IBRX Nearby Strikes · Nov 13, 2026
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.